Literature DB >> 2553243

A cell kinetic study of pulmonary adenocarcinoma by an immunoperoxidase procedure after bromodeoxyuridine labeling.

K Yoshida1, S Morinaga, Y Shimosato, Y Hayata.   

Abstract

By in vitro labeling with bromodeoxyuridine (BrdU) and immunohistochemical staining with anti-BrdU monoclonal antibody, the tumor cell kinetics were investigated in 52 resected pulmonary adenocarcinomas. The values of the BrdU labeling index (LI) varied widely among cases of adenocarcinoma in comparison with four cases of small cell carcinoma and ten cases of squamous cell carcinoma examined as controls. The LI was below 3.0 in 60% of the adenocarcinomas. When the LI was analyzed according to the cytologic subtypes of adenocarcinoma, the values were low for goblet cell type and type II alveolar cell type, whereas the values for the bronchial surface epithelial cell type varied widely (average, 5.2) and those for the Clara cell type were intermediate (average, 1.8). A comparison of the LI with TNM classification, histologic differentiation, degree of nuclear atypia, and mitotic cell count showed a correlation between the LI and each of these prognostic factors. Thus, the possibility of the BrdU LI being a useful new prognostic factor of pulmonary adenocarcinomas was suggested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553243     DOI: 10.1002/1097-0142(19891201)64:11<2284::aid-cncr2820641118>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Tumor extension and cell proliferation in adenocarcinomas of the lung.

Authors:  M Shoji; Y Dobashi; S Morinaga; S X Jiang; T Kameya
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

Review 2.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

3.  Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas.

Authors:  Y Dobashi; M Shoji; S X Jiang; M Kobayashi; Y Kawakubo; T Kameya
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

4.  PCNA immunostaining combined with AgNOR staining in esophageal squamous cell carcinoma to identify patients with a poor prognosis.

Authors:  Y Morisaki; S Shima; Y Yoshizumi; Y Sugiura; S Tanaka; S Tamai
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

5.  Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index.

Authors:  Y Tokuda; K Mukai; Y Matsuno; S Furuya; Y Shimosato; Y Takasaki; T Saida; K Ishihara
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

6.  Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data.

Authors:  G Fontanini; R Pingitore; D Bigini; S Vignati; S Pepe; A Ruggiero; P Macchiarini
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

7.  Expression of PCNA and p53 in esophageal dysplasia and esophageal carcinoma.

Authors:  S Murakami; Y Uchida; S Takeno; T Noguchi; K Matsumoto; H Shimoda
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.